Accelerating Breakthrough Discoveries into Medicines



Orca Pharmaceuticals and AstraZeneca Announce Development Partnership

Oxford, UK – February 25, 2015
Orca Pharmaceuticals, a BioMotiv portfolio company, and AstraZeneca announced a partnership to develop inhibitors against a wide range of autoimmune diseases. Orca will receive upfront and milestone payments from AstraZeneca with a potential total value of $122.5 million.

Click to view full release

Press ReleaseMaria Oldenburg